INSIGHT 2 : a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Bron
Future oncology - ISSN 1479-6694- () p.
Auteur(s)
    Egbert F. Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M. Tho, Xiuning Le, Julien Mazieres, How S. Hin, Masahire Morise, Viola W. Zhu, Daniel Tan, Kristina H. Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M. Schumacher, Niki Karachaliou, Yi-Long Wu

Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer long-term follow-up of the VISION phase 2 nonrandomized clinical trial

Bron
JAMA oncology - ISSN 2374-2437-9:9 (2023) p. 1260-1266
Auteur(s)
    Julien Mazieres, Paul K. Paik, Marina C. Garassino, Xiuning Le, Hiroshi Sakai, Remi Veillon, Egbert F. Smit, Alexis B. Cortot, Jo Raskin, Santiago Viteri, Yi-Long Wu, James C.H. Yang, Myung-Ju Ahn, Rui Ma, Jun Zhao, Aurora O'Brate, Karin Berghoff, Rolf Bruns, Gordon Otto, Andreas Johne, Enriqueta Felip, Michael Thomas

Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma

Bron
Frontiers in immunology - ISSN 1664-3224-14 (2023) p. 1-11
Auteur(s)
    Megane Willems, Arnaud Scherpereel, Eric Wasielewski, Jo Raskin, Helene Brossel, Alexis Fontaine, Melanie Gregoire, Louise Halkin, Majeed Jamakhani, Vincent Heinen, Renaud Louis, Bernard Duysinx, Malik Hamaidia, Luc Willems

Plain language summary of the development of tepotinib : a treatment for a subtype of non-small cell lung cancer called 'MET exon 14 skipping'

Bron
Future oncology - ISSN 1479-6694-19:10 (2023) p. 679-736
Auteur(s)
    John Hallick, Anne-Marie Baird, Gerald Falchook, Xiuning Le, David Hong, Santiago Viteri, Jo Raskin, Niels Reinmuth, Soetkin Vlassak, Mihaela Militaru, Paul K. Paik